Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Valoctocogene Roxaparvovec-rvox (Roctavian) No Longer in the TMPPM Effective August 1, 2026

Last updated on

On August 1, 2026, the Texas Medicaid & Healthcare Partnership (TMHP) will remove benefit information about valoctocogene roxaparvovec-rvox (Roctavian) from the Texas Medicaid Provider Procedures Manual (TMPPM), Outpatient Drug Services Handbook. TMHP will make this change because the drug is no longer available on the market.

For more information, call the TMHP Contact Center at 800-925-9126.

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.